<?xml version="1.0" encoding="UTF-8"?>
<ref id="B41-vaccines-08-00142">
 <label>41.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Perez-Zsolt</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Erkizia</surname>
    <given-names>I.</given-names>
   </name>
   <name>
    <surname>Pino</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>García-Gallo</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Martin</surname>
    <given-names>M.T.</given-names>
   </name>
   <name>
    <surname>Benet</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Chojnacki</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Fernández-Figueras</surname>
    <given-names>M.T.</given-names>
   </name>
   <name>
    <surname>Guerrero</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Urrea</surname>
    <given-names>V.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Anti-Siglec-1 antibodies block Ebola viral uptake and decrease cytoplasmic viral entry</article-title>
  <source>Nat. Microbiol.</source>
  <year>2019</year>
  <volume>4</volume>
  <fpage>1558</fpage>
  <lpage>1570</lpage>
  <pub-id pub-id-type="doi">10.1038/s41564-019-0453-2</pub-id>
  <pub-id pub-id-type="pmid">31160823</pub-id>
 </element-citation>
</ref>
